Hypoxic hepatitis as a manifestation of a new coronavirus infection
- Authors: Abyzov A.S1, Tarasova L.V1, Busalaeva E.I1,2
-
Affiliations:
- Chuvash State University named after I.N. Ulyanov
- Institute of Postgraduate Medical Education of the Ministry of Healthcare of Chuvash Republic
- Issue: No S1 (2022)
- Pages: 3-9
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288837
- DOI: https://doi.org/10.18565/therapy.2022.2suppl.3-9
- ID: 288837
Cite item
Open Access
Access granted
Abstract
The liver is one of the target organs for a new coronavirus infection. The pathogenesis of coronavirus infection is multifactorial, one of the possible causes is hypoxia, which develops due to respiratory failure, which is a distinctive feature of COVID-19. Literature data on the pathogenesis of liver damage in a new coronavirus infection, including liver damage as a result of hypoxia, are presented.
Full Text
About the authors
A. S Abyzov
Chuvash State University named after I.N. Ulyanov
L. V Tarasova
Chuvash State University named after I.N. Ulyanov
E. I Busalaeva
Chuvash State University named after I.N. Ulyanov; Institute of Postgraduate Medical Education of the Ministry of Healthcare of Chuvash Republic
References
- Metawea M.I., Yousif W.I., Moheb I. COVID 19 and liver: An A-Z literature review. Dig Liver Dis. 2021; 53(2): 146-52. doi: 10.1016/j.dld.2020.09.010.
- Amin M. COVID-19 and the liver: Overview. Eur J Gastroenterol Hepatol. 2021; 33(3): 309 doi: 10.1097/MEG.0000000000001808.
- Chai X., Hu L., Zhang Y. et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. doi: 10.1101/2020.02.03.931766
- Idalsoaga F., Ayares G., Arab J.P., Diaz L.A. COVID-19 and indirect liver injury: A narrative synthesis of the evidence. J Clin Transl Hepatol. 2021; 9(5): 760-68. doi: 10.14218/JCTH.2020.00140.
- Lightsey J.M., Rockey D.C. Current concepts in ischemic hepatitis. Curr Opin Gastroenterol. 2017; 33(3): 158-63. doi: 10.1097/MOG.0000000000000355.
- Premkumar M., Kedarisetty C.K. Cytokine storm of COVID-19 and its impact on patients with and without chronic liver disease. J Clin Transl Hepatol. 2021; 9(2): 256-64. doi: 10.14218/JCTH.2021.00055.
- Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475-81. doi: 10.1016/S2213-2600(20)30079-5.
- Tian D., Ye Q. Hepatic complications of COVID-19 anditstreatment. J Med Virol. 2020; 92(10): 1818-24. doi: 10.1002/jmv.26036.
- Feng G., Zheng K.I., Yan Q.Q. et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020; 8(1): 18-24. doi: 10.14218/JCTH.2020.00018.
- Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 15 (22.02.2022). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/BMP_COVID-19_V15.pdf (дата обращения - 01.03.2022).
- Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-22. doi: 10.1016/S2213-2600(20)30076-X.
- Zippi M., Fiorino S., Occhigrossi G., Hong W. Hypertransaminasemia in the course of infection with SARS-CoV-2: Incidence and pathogenetic hypothesis. World J Clin Cases. 2020; 8(8): 1385-90. doi: 10.12998/wjcc.v8.i8.1385.
- Rey J.R., Caro-Codon J., Rosillo S.O. et al.; CARD-COVID Investigators. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; 22(12): 2205-15. doi: 10.1002/ejhf.1990.
- Aghemo A., Piovani D., Parigi T.L. et al.; Humanitas COVID-19 Task Force. COVID-19 digestive system involvement and clinical outcomes in a Large Academic Hospital in Milan, Italy. Clin Gastroenterol Hepatol. 2020; 18(10): 2366-68.e3. doi: 10.1016/j.cgh.2020.05.011.
- Wang Y., Liu S., Liu H. et al. SARS-CoV-2 infection of the liver directly contributes o hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4): 807-16. doi: 10.1016/j.jhep.2020.05.002.
- Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-22. doi: 10.1016/S2213-2600(20)30076-X.
- Sharma A., Jaiswal P., Kerakhan Y. et al. Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis. Ann Hepatol. 2021; 21: 100273. doi: 10.1016/j.aohep.2020.10.001.
- Del Zompo F., De Siena M., Ianiro G. et al. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: Systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020; 24(24): 13072-88. doi: 10.26355/eurrev_202012_24215.
- Huang H., Li H., Chen S. et al. Prevalence and characteristics of hypoxic hepatitis in COVID-19 Patients in the Intensive Care Unit: a first retrospective study. Front Med (Lausanne). 2021; 7: 607206. doi: 10.3389/fmed.2020.607206.
Supplementary files
